BSX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Boston Scientific Corp (BSX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown solid financial growth in Q4 2025 and Congress trading data indicates positive sentiment, the recent product recall, insider selling, and reduced analyst price targets suggest caution. The technical indicators are mixed, with bearish moving averages and neutral RSI, and there are no strong proprietary trading signals to support immediate action. A hold position is recommended until more clarity emerges on the company's operational stability and growth catalysts.
The MACD is positive and expanding, suggesting bullish momentum, but the RSI is neutral at 48.719. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a downtrend. Key support and resistance levels are Pivot: 75.026, R1: 76.443, S1: 73.608, R2: 77.318, S2: 72.733.
Congress members have made significant purchases of BSX stock, indicating positive sentiment.
Strong Q4 2025 financial performance with revenue up 15.90% YoY and net income up 18.94%.
Product recall of AXIOS stents and delivery systems due to serious complications.
Insider selling has increased by 755.62% over the last month.
Analysts have lowered price targets, citing missed expectations in key segments and increased competition.
In Q4 2025, Boston Scientific reported revenue of $5.286 billion (+15.90% YoY), net income of $672 million (+18.94% YoY), EPS of $0.45 (+18.42% YoY), and gross margin of 65.38% (+3.76% YoY).
Analysts have lowered price targets across the board, with targets now ranging from $94 to $115. Despite this, most analysts maintain a Buy or Outperform rating, citing the company's long-term growth potential but acknowledging short-term challenges.
